Nifong T.P.,Metamark Genetics |
McDevitt T.J.,Elizabethtown College
Chest | Year: 2011
Background: Catheter-related thrombosis is a common complication in all anatomic sites, especially when smaller veins of the upper extremity are considered. It is presumed that the presence of a catheter within the lumen of a vein will decrease flow and potentially create stasis, and clinical data suggest that the size of the catheter impacts thrombosis rates. We sought to determine, both mathematically and experimentally, the impact of catheters on fluid flow rates. Methods: We used fluid mechanics to calculate relative flow rates as a function of the ratio of the catheter to vein diameters. We also measured the flow rate of a blood analyte solution in an annular flow model using diameters that simulate the size of upper extremity veins and commonly used peripherally inserted central catheters (PICCs). Results: We compared each of the derived relative flow rates to the experimentally determined ones for three cylinder sizes and found a correlation of r2 = 0.90. We also confirmed that the decrease in fluid flow rate with each successive catheter size is statistically significant (P<.0001). Conclusions: Our results demonstrate that fluid flow is dramatically decreased by the insertion of a centrally located obstruction. Assuming that blood flow in veins behaves in a similar manner to our models, PICCs, in particular, may substantially decrease venous flow rates by as much as 93%. © 2011 American College of Chest Physicians.
Metamark Genetics | Date: 2014-03-14
Provided herein are methods, e.g., computer-implemented methods or automated methods, of evaluating a cancer sample, e.g., a prostate tumor sample, from a patient. Also provided are biomarker panels for prognosticating prostate cancer. Also provided are methods of treating prostate cancer by identifying aggressive prostate cancer or prostate cancer that may have lethal outcome.
Metamark Genetics | Date: 2014-04-22
Panels of genetic markers and/or proteins used for scientific testing, analyzing and evaluating cancer cells, circulating tumor cells, and biopsies in the field of cancer for malignant tumors. Panels of genetic markers and/or proteins used for testing, analyzing and evaluating cancer cells, circulating tumor cells, and biopsies in the field of cancer for malignant tumors.
News Article | December 23, 2011
Our partnership with the folks at WGBH continues as we join forces again this week to bring you the Xconomy Report. In this week’s innovation news, TripAdvisor goes public and independent, breaking ties with Expedia. Seattle-based Amazon.com makes plans for a Boston-area office, which will open in Cambridge early next year. And much more, including news from Akamai, Nuance, and Metamark Genetics. In case you missed it this morning, have a listen below. The Xconomy Report airs every Friday at 7:49am on 89.7FM.
News Article | August 23, 2010
Startup Investing in Massachusetts Shrinks to $131M in July, Big Drop From June Surge It looks like the lazy days of summer are in full swing. While equity financing deals for Massachusetts startups surged in June to hit a total of $307 million, investors took a bit of a break in July. Last month, Bay State tech and life sciences startups raised less than half their June sum, $131.4 million brought in by 26 equity-based financings. That number was also far below the roughly $200 million that startups had been raising in most of the months before June, based on data provided by private company intelligence platform CB Insights. The massive June startup investment pot was led by a $60 million deal for lithium-ion battery maker Boston-Power (the company added another $6.4 million to its financing last month). By comparison, July’s biggest deal was less than half that, a $24 million Series A round for Euthymics Bioscience. Last month, Luke wrote about how the Cambridge, MA-based startup is developing a treatment for depression that it says lacks the side effects of existing medications on the market. The runner-up July deal went to another biotech, Metamark Genetics, which is developing diagnostics technology to track genetic markers as indicators of tumor progression. The company, which started out in Florida but is making a move to Cambridge, raised $22 million in a Series B financing. In July, healthcare deals kept up their typical pattern of accounting for nearly half of the month’s sum of investments in startups. But even as the top sector, the total investment in July healthcare startups was nearly $100 million less than the sum raised by healthcare startups in June. A few interesting Internet startups nabbed some of the top deals in July. BuyWithMe grabbed a $16 million Series B investment led by Bain Capital Ventures. The Boston company is in the social buying space occupied by companies like Groupon, LivingSocial, and DealPop. Electronics trading and selling service Gazelle was another Internet company that attracted funding last month. The Boston startup raised $12 million in Series C money to help meet the demand from its growing customer base, develop partnerships with retailers, and enhance its pricing technology that determines how much a seller can get for used electronics. Overall, Internet applications especially outshone more traditional software companies when it came to raising money in July. The Internet sector pulled in nearly $37 million dollars in seven deals. But there was only one non-Internet software deal in July, worth a mere $100,000. Traditional software investments seemed to be slowing down in the past few months, but July’s dealmaking was by far the most stagnant we had seen yet. It’s hard to see why the drastic drop in startup investing occurred over just one month, so we’ll have to wait till next month to get the full picture of startup financings this summer in the Bay State. In the meantime, check out the full list below of equity deals for Massachusetts startups in July. There were also another seven non-equity deals last month, which brought in a total of $14.25 million. See below for the details.
News Article | February 24, 2011
Metamark, Stealthy Startup with Dana-Farber Roots, Seeks to Tell Docs When to Treat Prostate Cancer, and When Not Metamark Genetics has graduated from stealth mode. Now the Cambridge, MA-based startup, founded by top scientists at Harvard University and elsewhere, has hired a diagnostics industry veteran as its chief executive, and set a public goal for releasing a product that could change the way physicians decide how to treat prostate cancer in its early stages. Mark Straley, the company’s chief executive, says he joined the company in November 2010 after serving as president of the healthcare giant Johnson & Johnson’s (NYSE:JNJ) global diagnostics group. He joined other heavy hitters at the startup such as Kenneth Weg, the company’s co-founder and chairman, who was previously the chairman of the cancer drug maker Millennium Pharmaceuticals (sold to Takeda Pharmaceuticals for $8.8 billion in 2008). Also, Lynda Chin, a scientific founder from Dana-Farber Cancer Institute in Boston, was part of the founding team at Aveo Pharmaceuticals (NASDAQ:AVEO), another Cambridge cancer drug developer that’s been on a roll of late. Now Straley, who says he previously had about 1,500 people working under him at J&J, is wearing multiple hats as chief of a 20-person startup that hasn’t yet made a big name for itself in the diagnostics world. The company, founded in 2007, has raised about $30 million from undisclosed investors. But, according to the big plans the CEO laid out to me, the company’s star might rise pretty quickly over the next couple of years. Metamark aims to release a molecular test to provide prognostic information that will help physicians make better treatment decisions. This test is scheduled to be available in the second quarter of 2012, Straley says. The firm raised its profile in the scientific community this month when some of its academic founders published their findings, in the prestigious academic journal Nature, about four gene markers that help predict whether a man’s prostate cancer is programmed to spread to other organs or is relatively harmless. This could give doctors more data with which to decide whether to take aggressive actions against the tumors (such as surgical removal and chemotherapy) or to basically just monitor the disease. The startup is using those findings—based on the work of its co-founder Ron DePinho (another Aveo founder), the director of Dana-Farber Cancer Institute’s Belfer Institute of Applied Cancer Science, and others—to develop a panel of gene markers for its prostate cancer test, Straley says. Today, doctors can take tissue samples from the prostate and inspect the cells under a microscope, which can give them clues about whether the tumor could become lethal or remain relatively docile. Yet Metamark’s test in development might be able to expose the true nature of the cancer at the molecular level. “We have to do a better job of … Next Page »
News Article | July 13, 2010
Metamark Genetics has new funding to find which tumors are deadly and poised to spread out of control. The startup, which is commercializing technology discovered at Harvard Medical School, said today it has closed a $22 million Series B round of financing. Its lead investor in the round has agreed to chip in an additional $8 million if the firm reaches an undisclosed goal. The company, which lists a Naples, FL, address in this regulatory disclosure of the financing, says on its website that it’s in the process of relocating its headquarters to Cambridge, MA. Eric Devroe, the firm’s senior director of operations, said in an e-mail that the company is finalizing a lease on a lab in Cambridge and expects to occupy the space within the next few weeks. Metamark, which previously raised $4.7 million, declined to disclose who invested in its second-round financing. The deal could ultimately be worth as much as $42.1 million, according to the regulatory filing. Perseus, a merchant bank and private equity firm based in Washington, DC, is represented on Metamark’s board of directors. Kenneth Weg, who was chairman of Millennium Pharmaceuticals in Cambridge until Japan-based Takeda Pharmaceutical Company bought the Millennium in 2008 for $8.8 billion, is a co-founder and acting CEO at Metamark. Weg is also a former president of the worldwide medicines group at Bristol-Myers Squibb. Metamark is developing a diagnostics to identify genetic markers and quantify other drivers of tumor progression, like molecules that show whether a tumor is destined to spread to other organs. It was founded in 2007 based on the research of Harvard Medical School dermatology professor Lynda Chin, who has a lab at the renowned Dana-Farber Cancer Institute in Boston. The founding team also includes other notable names, including Raju Kucherlapati, the Harvard Medical School professor and co-founder of Cell Genesys, Abgenix, and Millennium; and Ronald DePinho, another Harvard Medical School professor and co-founder of Cambridge-based Aveo Pharmaceuticals.
News Article | March 25, 2015
National recruitment firm Slone Partners is pleased to announce the placement of Michael Hoffman as Director of National Accounts at Metamark Genetics. At Metamark, Mr. Hoffman will develop and execute the strategic and tactical initiatives to secure and support payers, both regional and national. “The ability to gain market access and strengthen relationships with payers is a top priority in today’s environment,” said Metamark CEO Shawn Marcell. “I am proud to announce the addition of Michael Hoffman to the Metamark team. With his expertise in market access and payer relations, Metamark will continue to lead innovation in prostate cancer and aid patients and healthcare professionals in making important decisions about treatment.” Mr. Hoffman brings 15 years of successful market access strategies and healthcare trending insights in the diagnostics, genetic, personalized medicine, pharmaceutical, and biotech industries, most recently as Senior Director of Managed Care at Courtagen Life Sciences. At Courtagen, Mr. Hoffman managed commercial and government accounts for the company’s genetic diagnostics book of business, interfacing with payers’ diagnostic leaders and pharmacy leaders to broaden business in the pharmacogenomics and personal medicine arenas. Prior to Courtagen, Mr. Hoffman was Senior Director of Managed Care at Transgenomic Health / PGx Health, where he was the lead for all managed market strategies and tactics. Metamark is a privately held company dedicated to improving cancer care by providing the next generation of diagnostic and prognostic testing. The company is advancing its contribution to oncology through its proprietary genomics and proteomics discovery platforms, a growing clinical research effort, and corporate alliances. Metamark has assembled a unique portfolio of testing services and products to inform critical decisions at each step of the care pathway in prostate cancer. The company’s interests also include bladder, colon, and breast cancers. For more information, please visit the Metamark website at http://www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark. Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life science tools, healthcare information technology, and laboratory testing industries. Slone Partners has offices in Boston, New York, Washington, D.C., and San Francisco. For more information on Slone Partners placements, please visit http://www.slonepartners.com.
News Article | November 3, 2016
BELTSVILLE, Md., Nov. 3, 2016 /PRNewswire/ -- P4 Diagnostix™ Laboratory Network announced today the acquisition of Metamark Laboratories, Inc., formerly a division of Metamark Genetics, Inc. The acquisition of Metamark Laboratories expands the geographic reach, insurance base, and u...